Comparison Among 3 Interpretation Criteria for 68Ga-PSMA PET
| Parameter | EANM (9) | PROMISE (10) | PSMA-RADS (11) |
| Summary | All areas of increased PSMA uptake in sites not expected to show physiologic uptake are to be reported as “anomalous,” followed by subclassification to 3 categories | Both CT/MRI appearance and PSMA uptake are considered, and diagnosis is judged as “positive,” “equivocal,” or “negative” for each site | All abnormal findings are classified by 5-point scale based on possibility of cancerous lesion |
| Definition of significant uptake | Focal uptake higher than adjacent background | Basically, uptake equal to or above liver | Not clearly defined |
| Lesion site | Local sites, local lymph nodes, distant lymph nodes, skeletal, other | Local sites before and after treatment, lymph nodes, bone/visceral organ | Bone, soft tissue (including lymph nodes) |
| Classification in each site | Anomalous, pathologic, uncertain, nonpathologic, normal | Positive, equivocal, negative | 5: PC almost certainly present; 4: PC highly likely; 3: equivocal (3A–D); 2: likely benign; 1: benign (1A/B) |
| Final judgment | Abnormal (pathologic), normal | Positive, equivocal, or negative, plus miTNM classification | Highest PSMA-RADS score among detected lesions |
miTNM = molecular imaging TNM.